197 related articles for article (PubMed ID: 22709466)
1. Anticoagulant for primary percutaneous coronary intervention - the last dance for unfractionated heparin?
Silvain J; Montalescot G
Arch Cardiovasc Dis; 2012 May; 105(5):259-61. PubMed ID: 22709466
[No Abstract] [Full Text] [Related]
2. Bivalirudin in percutaneous coronary intervention, is it the anticoagulant of choice?
Mahmoud A; Saad M; Elgendy AY; Abuzaid A; Elgendy IY
Cardiovasc Ther; 2015 Aug; 33(4):227-35. PubMed ID: 25879426
[TBL] [Abstract][Full Text] [Related]
3. The changing horizon of acute coronary syndrome.
de Silva R; Fox KM
Lancet; 2009 Oct; 374(9696):1125-7. PubMed ID: 19717183
[No Abstract] [Full Text] [Related]
4. Unfractionated versus low-molecular-weight heparin for primary angioplasty-More data suggesting to go low.
Moliterno DJ
Catheter Cardiovasc Interv; 2011 Feb; 77(2):191-2. PubMed ID: 21290553
[No Abstract] [Full Text] [Related]
5. Effect of bivalirudin compared with unfractionated heparin plus abciximab on infarct size and myocardial recovery after primary percutaneous coronary intervention: the horizons-AMI CMRI substudy.
Wöhrle J; Merkle N; Kunze M; Cristea E; Mehran R; Rottbauer W; Stone GW
Catheter Cardiovasc Interv; 2012 Jun; 79(7):1083-9. PubMed ID: 22162175
[TBL] [Abstract][Full Text] [Related]
6. Comparison of bivalirudin with heparin versus abciximab with heparin for primary percutaneous coronary intervention in "Real World" practice.
Showkathali R; Davies JR; Parker M; Taggu W; Tang KH; Clesham GJ; Gamma RA; Sayer JW; Aggarwal RK; Kelly PA
Cardiovasc Revasc Med; 2013; 14(5):289-93. PubMed ID: 23972537
[TBL] [Abstract][Full Text] [Related]
7. Bivalirudin versus heparin plus a glycoprotein IIb/IIIa inhibitor in patients with non-ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention after clopidogrel pretreatment: pooled analysis from the ACUITY and ISAR-REACT 4 trials.
Ndrepepa G; Neumann FJ; Deliargyris EN; Mehran R; Mehilli J; Ferenc M; Schulz S; Schömig A; Kastrati A; Stone GW
Circ Cardiovasc Interv; 2012 Oct; 5(5):705-12. PubMed ID: 23048052
[TBL] [Abstract][Full Text] [Related]
8. Bivalirudin versus unfractionated heparin during percutaneous coronary intervention in patients with non-ST-segment elevation acute coronary syndrome initially treated with fondaparinux: results from an international, multicenter, randomized pilot study (SWITCH III).
Waksman R; Bertrand O; Driesman M; Gruberg L; Rossi J; Mehta S; Swymelar S; Dvir D; Xue Z; Torguson R
J Interv Cardiol; 2013 Apr; 26(2):107-13. PubMed ID: 23240743
[TBL] [Abstract][Full Text] [Related]
9. Frequency and predictors of stent thrombosis after percutaneous coronary intervention in acute myocardial infarction.
Dangas GD; Caixeta A; Mehran R; Parise H; Lansky AJ; Cristea E; Brodie BR; Witzenbichler B; Guagliumi G; Peruga JZ; Dudek D; Möeckel M; Stone GW;
Circulation; 2011 Apr; 123(16):1745-56. PubMed ID: 21482968
[TBL] [Abstract][Full Text] [Related]
10. Safety and efficacy of bivalirudin with and without glycoprotein IIb/IIIa inhibitors in patients with acute coronary syndromes undergoing percutaneous coronary intervention 1-year results from the ACUITY (Acute Catheterization and Urgent Intervention Triage strategY) trial.
White HD; Ohman EM; Lincoff AM; Bertrand ME; Colombo A; McLaurin BT; Cox DA; Pocock SJ; Ware JA; Manoukian SV; Lansky AJ; Mehran R; Moses JW; Stone GW
J Am Coll Cardiol; 2008 Sep; 52(10):807-14. PubMed ID: 18755342
[TBL] [Abstract][Full Text] [Related]
11. Anticoagulant therapy for percutaneous coronary intervention.
Rao SV; Ohman EM
Circ Cardiovasc Interv; 2010 Feb; 3(1):80-8. PubMed ID: 20160186
[No Abstract] [Full Text] [Related]
12. Bivalirudin in patients with heparin-induced thrombocytopenia undergoing percutaneous coronary intervention.
Campbell KR; Mahaffey KW; Lewis BE; Weitz JI; Berkowitz SD; Ohman EM; Califf RM
J Invasive Cardiol; 2000 Dec; 12 Suppl F():14F-9. PubMed ID: 11156729
[No Abstract] [Full Text] [Related]
13. Efficacy and safety of enoxaparin versus unfractionated heparin during percutaneous coronary intervention: systematic review and meta-analysis.
Silvain J; Beygui F; Barthélémy O; Pollack C; Cohen M; Zeymer U; Huber K; Goldstein P; Cayla G; Collet JP; Vicaut E; Montalescot G
BMJ; 2012 Feb; 344():e553. PubMed ID: 22306479
[TBL] [Abstract][Full Text] [Related]
14. Heparin or enoxaparin anticoagulation for primary percutaneous coronary intervention.
Brieger D; Collet JP; Silvain J; Landivier A; Barthélémy O; Beygui F; Bellemain-Appaix A; Mercadier A; Choussat R; Vignolles N; Costagliola D; Montalescot G
Catheter Cardiovasc Interv; 2011 Feb; 77(2):182-90. PubMed ID: 20578166
[TBL] [Abstract][Full Text] [Related]
15. Heparin monotherapy or bivalirudin during percutaneous coronary intervention in patients with non-ST-segment-elevation acute coronary syndromes or stable ischemic heart disease: results from the Evaluation of Drug-Eluting Stents and Ischemic Events registry.
Bangalore S; Pencina MJ; Kleiman NS; Cohen DJ
Circ Cardiovasc Interv; 2014 Jun; 7(3):365-73. PubMed ID: 24736878
[TBL] [Abstract][Full Text] [Related]
16. Percutaneous coronary intervention in patients with acute coronary syndrome: focus on bivalirudin.
Ramana RK; Lewis BE
Vasc Health Risk Manag; 2008; 4(3):493-505. PubMed ID: 18827868
[TBL] [Abstract][Full Text] [Related]
17. Influence of timing of clopidogrel treatment on the efficacy and safety of bivalirudin in patients with non-ST-segment elevation acute coronary syndromes undergoing percutaneous coronary intervention: an analysis of the ACUITY (Acute Catheterization and Urgent Intervention Triage strategY) trial.
Lincoff AM; Steinhubl SR; Manoukian SV; Chew D; Pollack CV; Feit F; Ware JH; Bertrand ME; Ohman EM; Desmet W; Cox DA; Mehran R; Stone GW;
JACC Cardiovasc Interv; 2008 Dec; 1(6):639-48. PubMed ID: 19463378
[TBL] [Abstract][Full Text] [Related]
18. The vulnerable endothelium: priming the vascular endothelium for thrombosis with unfractionated heparin: biologic plausibility for observations from the Superior Yield of the New Strategy of Enoxaparin, Revascularization and Glycoprotein IIb/IIIa Inhibitors (SYNERGY) trial (Am J Heart 2005;150:189-92).
Aggarwal A
Am Heart J; 2006 May; 151(5):e2. PubMed ID: 16644303
[No Abstract] [Full Text] [Related]
19. Anticoagulation for acute coronary syndromes: from heparin to direct thrombin inhibitors.
Lepor NE
Rev Cardiovasc Med; 2007; 8 Suppl 3():S9-17. PubMed ID: 17917621
[TBL] [Abstract][Full Text] [Related]
20. Impact of gender and antithrombin strategy on early and late clinical outcomes in patients with non-ST-elevation acute coronary syndromes (from the ACUITY trial).
Lansky AJ; Mehran R; Cristea E; Parise H; Feit F; Ohman EM; White HD; Alexander KP; Bertrand ME; Desmet W; Hamon M; Stone GW
Am J Cardiol; 2009 May; 103(9):1196-203. PubMed ID: 19406258
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]